Table 2.
Treatment prior to initiating lawsuit for biologics use
| Adalimumab 14 (6.9) |
Efalizumab 43 (21.2) |
Etanercept 35 (17.2) |
Infliximab 111 (54.7) |
Total 203 (100) |
|
|---|---|---|---|---|---|
| Therapies | |||||
| None | 1 (7.1) | 12 (27.9) | 6 (17.1) | 25 (22.5) | 44 (21.7) |
| Only topical | 0 | 0 | 0 | 0 | 0 |
| Only phototherapy | 0 (0.0) | 5 (11.6) | 3 (8.7) | 7 (6.3) | 15 (7.4) |
| Only N-BIOSYS* | 10 (71.4) | 2 (4.6) | 12 (34.3) | 36 (32.4) | 60 (29.6) |
| Combination of therapies prior to the use of biologics, n (%) | |||||
| Topical+phototherapy | 0 | 0 | 0 | 0 | 0 |
| Topical+N-BIOSYS* | 1 (7.1) | 4 (9.3) | 3 (8.6) | 16 (14.4) | 24 (11.8) |
| Phototherapy+N-BIOSYS* | 2 (14.3) | 18 (41.8) | 8 (22.8) | 22 (19.8) | 50 (24.6) |
| Topical+phototherapy+N-BIOSYS* | 0 (0.0) | 2 (4.6) | 3 (8.6) | 5 (4.5) | 10 (4.9) |
| Recommended use of biological agents according to guidelines (7–10), n (%) | |||||
| Topical+N-BIOSYS | 1 (7.1) | 6 (14.0) | 6 (17.1) | 21 (18.9) | 34 (16.7) |
*Acitretin, methotrexate and ciclosporin.
N-BIOSYS, non-biological systemic.